Tranzyme (TZYM) -66% premarket after reporting negative preliminary results from the first of two trials assessing its TZP-102 treatment for diabetic patients with a common stomach complication. Neither the 10mg dose group nor the 20mg dose group of TZP-102 patients reached statistical significance vs. a placebo.
Tranzyme (TZYM) -66% premarket after reporting negative preliminary results from the first of...
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs